Status:
UNKNOWN
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University
Conditions:
Lymphoma
Multiple Myeloma
Eligibility:
All Genders
18-80 years
Phase:
EARLY_PHASE1
Brief Summary
Chemokine receptor CXCR4 is normally expressed on T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils and eosinophils as well as hematopoietic stem and progenitor cells (HSPC) in the bon...
Detailed Description
Lymphoma: The marginal zone lymphoma, plasma cell lymphoma, T-cell-lymphoma frequently do not present with an elevated FDG uptake. However, lymphoma is a frequent cancer with high CXCR4 expression. T...
Eligibility Criteria
Inclusion
- suspected or confirmed untreated Lymphoproliferative diseases patients
- 18F-FDG PET/CT within two weeks
- signed written consent.
Exclusion
- pregnancy
- breastfeeding
- known allergy against Pentixafor
Key Trial Info
Start Date :
August 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04504526
Start Date
August 7 2020
End Date
December 1 2024
Last Update
September 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005